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Lung cancer is the most deadly type of cancer in humans, with non-small-cell lung cancer
(NSCLC) being the most frequent and aggressive type of lung cancer showing high resis-
tance to radiation and chemotherapy. Despite the outstanding progress made in anti-tumor
therapy, discovering effective anti-tumor drugs is still a challenging task. Here we describe
a new semisynthetic derivative of cucurbitacin B (DACE) as a potent inhibitor of NSCLC cell
proliferation. DACE arrested the cell cycle of lung epithelial cells at the G2/M phase and in-
duced cell apoptosis by interfering with EGFR activation and its downstream signaling, in-
cluding AKT, ERK, and STAT3. Consistent with our in vitro studies, intraperitoneal
application of DACE significantly suppressed the growth of mouse NSCLC that arises from
type II alveolar pneumocytes due to constitutive expression of a human oncogenic c-RAF
kinase (c-RAF-1-BxB) transgene in these cells. Taken together, these findings suggest that
DACE is a promising lead compound for the development of an anti-lung-cancer drug.
Introduction
Lung cancer is the most deadly type of cancer in humans causing approximately 1.38 million
deaths annually worldwide [1]. The most common form is non-small-cell lung cancer
(NSCLC), and adenocarcinoma is the most prevalent histology present in 50% of all NSCLCs
[2]. There is an unquestionable urge to develop new and effective treatments for the manage-
ment of this cancer.
One of the well-known hallmarks of cancer is the deregulation of apoptosis (i.e., pro-
grammed cell death) [3]. Several promising targets for intervention have been identified by
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studying the molecular abnormalities that underlie tumorigenesis, such as the signal transduc-
tion pathways that regulate apoptosis. One of these targets is the epidermal growth factor re-
ceptor (EGFR), which is a member of the ErbB family with signal-transducing tyrosine kinase
activity, located in or at the cell membrane [4]. EGFR activation triggers a network of signal
transduction cascades that includes activation of PI3K/AKT, RAS/RAF/ERK, and JAK/STAT
signaling pathways. These pathways lead to stimulation or inhibition of transcription factors
that regulate expression of both pro- and anti-apoptotic genes, effectively disturbing the apo-
ptotic machinery [4,5]. EGFR has been implicated in regulating growth and survival of
NSCLC, with overexpression occurring in 45% to 70% of the cases, which is also accompanied
by a constitutive activation of the major downstream EGFR effector proteins including PI3K
[6], AKT [7], ERK [8], and STAT3 [9].
Natural plant products have been traditionally used for preventing and treating several
diseases, including cancer [10]. Moreover, natural products serve as an important source of
chemotherapeutic drugs [11,12] and hence approximately 59% of commercially available anti-
cancer drugs were directly or indirectly originated from natural sources [13].
In this perspective, cucurbitacins and their derivatives have become a focus of research be-
cause of their strong capability to inhibit several types of cancers [14–17]. Cucurbitacins are a
group of diverse highly oxygenated triterpenoid molecules predominantly found in different
species of the Cucurbitaceae family. They are derived from the cucurbitane skeleton [19-
(10!9β)-abeo-10α-lanost-5-ene], which is known for having biological activities including
anti-inflammatory, anti-pyretic, analgesic, and hepatoprotective actions [14,18] but the most
relevant effects of these molecules are, without doubt, their cytotoxic effects toward a number
of human cancer cell lines such as those of the breast [19], lung [20–22], prostate [23,24], and
human colon [25,26].
Recently, we described novel cytotoxic cucurbitacins isolated fromWilbrandia ebracteata
Cogn. [21] and unraveled the apoptotic mechanism in NSCLC cells for the most active com-
pound [27]. We also described new semisynthetic derivatives of cucurbitacin B that are highly
cytotoxic against A549 cells [22]. In the present study, we have elucidated the in vitromecha-
nism of cell death induced by a new semisynthetic derivative of cucurbitacin B, the 2-deoxy-2-
amine-cucurbitacin E (Fig. 1) (named here as DACE) on A549 cells. We evaluated its effects on
cell growth, cell cycle distribution, apoptosis, morphological changes, and expression of regula-
tory proteins as well as signaling pathways involved in such processes. Furthermore, this potent
derivative was also evaluated in vivo in a transgenic mouse lung cancer model expressing a mu-
tated and constitutively active c-RAF kinase (c-RAF-1-BxB) under the control of the human
surfactant protein C (SP-C) promoter in type II alveolar pneumocytes [28].
Material and Methods
Semisynthesis of DACE
The natural precursor cucurbitacin B (200mg, 0.358mmol) was firstly converted into a tosy-
lated intermediate by reaction with p-toluenesulfonyl chloride (340mg, 1.432mmol) and
DABCO (200mg, 1.79mmol) in dichloromethane (2mL). The next step was the nucleophilic
substitution of the intermediate (200mg, 0.28mmol) using NaN3 (182mg, 2.8mmol) in DMF
(2.5mL), to afford DACE [22] (Fig. 1).
Cell lines
A549 (human non-small-cell lung cancer), NIH3T3 (immortalized mouse embryo fibroblasts),
and NIH3T3 sublines stably retrovirally transduced with RAF or RAS oncogenes [NIH3T3(v-
RAF) and NIH3T3(k-RAS), respectively] were described previously [27,29]. They were
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cultured in Dulbecco's modified Eagle medium (DMEM), supplemented with 10% heat-inacti-
vated fetal bovine serum (FBS), and maintained at 37°C with 5% CO2 and were authenticated
by Multiplexion in March 2013. All cell lines were thawed from early-passage frozen stocks
and were passaged less than 20 times prior to use. All cells were routinely monitored for micro-
bial and mycoplasma contamination.
Transient transfections and plasmids
A549 cells were transfected with Lipofectamine 2000 (Life Technologies, USA) according to
the manufacturer’s instructions. The plasmid p-ECFP-C1, encoding human EGFR fused to
cyan-fluorescent protein, was kindly provided by Dr. N. Zobiack (Institute for Medical Bio-
chemistry, Münster, Germany). Expression constructs for a wild-type form of AKT in pCMV5
were kindly provided by Dr. J. Troppmair (Daniel Swarovski Research Laboratory, University
of Innsbruck, Austria), and have been described before [30]. After 24h incubation at 37°C with
5% CO2, cells were treated with DACE for 24h and analyzed by Western blotting as
described below.
Cell viability assay
Cell viability was measured using MTT reduction assay [3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyl tetrazolium bromide] (Sigma, MO, USA) [31]. Briefly, cells were seeded in 96-well
culture plates (1x104cells/well) and, after 24h, treated with different concentrations of DACE;
48h or 72h later the medium was replaced by 50μL of MTT reagent (1mg/mL) and cells were
incubated for a further 4h, followed by reading on a scanning multi-well spectrophotometer
(Infinite 1200 TECAN, Grödje, Austria). The 50% inhibition concentration (IC50) was defined
as the concentration that inhibited cell proliferation by 50% when compared to untreated cells.
Paclitaxel (Sigma, MO, USA) (at 0–10μM) was used as a positive control. Final solvent concen-
tration showed no interference with cell growth (data not shown).
Clonogenic assay
For evaluation of colony-forming capability, the colony formation assay was performed [32].
First, A549 cells were treated for 48h with 0.5 and 1μM of DACE, followed by medium remov-
al. Cells were washed twice with PBS, harvested and reseeded at a density of 200 cells/well in
6-wells plates without treatment. Media was changed every 2 days. After 12 days, colonies were
fixed with methanol, followed by staining with 0.1% crystal violet. The plates were photo-
graphed, and the number of colonies was counted.
Fig 1. Scheme for preparation of a novel semisynthetic derivative of cucurbitacin B (DACE).
doi:10.1371/journal.pone.0117794.g001
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Cell cycle and apoptosis analysis by flow cytometry
To determine cell cycle progression, A549 cells (5×105) were exposed to DACE in 6-well plates
for 24h, washed twice with phosphate-buffered saline (PBS, pH 7.4), centrifuged at 500 X g for
5 min, and fixed with 70% ice-cold ethanol at 4°C for 30 min. After fixation, cells were treated
with 50μg/ml RNase, and stained with 100μg/ml propidium iodide (PI) for 30 min at room
temperature in the dark. Analysis was performed immediately after staining using a FACS Cali-
bur instrument (Becton Dickinson, BD, USA). The percentages of cells in each phase of the cell
cycle (G1, S, and G2/M) were determined using the CellQuest Pro software (BD).
Apoptotic populations of vehicle- or 12h DACE-treated cells were quantified using the dual
staining Annexin V-FITC/PI apoptosis detection kit (Sigma, MO, USA) according to the
manufacturer’s instructions.
Caspase assay
Caspase-3 protease activity was determined using a commercially available kit (Millipore, MA,
USA). Briefly, A549 cells (5x105/six-well) were treated with DACE for 12h. Cells were har-
vested and resuspended in 150μl of chilled cell-lysis buffer, incubated on ice for 10 min, and
centrifuged for 5 min (10,000 X g). Then the supernatants were transferred (cytosolic extract)
to fresh tubes and put on ice for immediate processing. Cell lysates were tested for protease ac-
tivity by the addition of a labeled caspase substrate (DEVD-pNA), and incubated at 37°C for
2h. pNA absorbance was quantified using a spectrophotometer (Infinite 1200 TECAN, Grödje,
Austria) at a wavelength of 405 nm. Fold-increase in caspase-3 activity was determined as a re-
lation of OD values from experimental to that of control samples.
Confocal laser scanning microscopy to visualize filamentous actin and
nuclei
A549 cells grown on coverslips placed into six-well plates were treated with vehicle or DACE
for 12h and then fixed in 4% (w/v) paraformaldehyde at 37°C. Following permeabilization in
0.5% (v/v) Triton X-100, the cells were incubated with TRITC-labeled-phalloidin (Invitrogen,
Carlsbad, USA) for F-actin staining, and with Hoechst (Invitrogen, Carlsbad, USA) to detect
nuclei. The coverslips were mounted with 80% glycerol in PBS and confocal images were col-
lected on a Leica DMI6000 B microscope (Leica Microsystems, Wetzlar, Germany).
Western blotting analysis
After treatment, cells were lysed on ice with RIPA lysis buffer (25mM Tris-HCl pH 8.0,
137mMNaCl, 10% glycerol, 0.1% SDS, 0.5% DOC, 1% NP40, 2mM EDTA pH 8.0, 5mg/mL
leupeptin, 5mg/mL aprotinin, 0.2mM pefablock, 1mM sodium vanadate, and 5mM benzami-
dine) for 30 min. Cell lysates were cleared by centrifugation and equal amounts of total protein
lysates were separated by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-
PAGE) and blotted on nitrocellulose membranes (Schleicher & Schuell, Dassel, Germany).
PI3K activity was monitored by detection of PI3K, PTEN, PDK1, and AKT phosphorylation.
The antibodies used were against: PI3Kinase p85 [Tyr458]/p55 [Tyr199], PTEN [Ser380/
Thr382/383], PDK1 [Ser241] purchased from Cell Signaling Technology, Danvers, USA (CST),
and AKT [Ser473] from Invitrogen. Phosphorylated forms of EGFR, ERK, and STAT3 were de-
tected with phosphospecific antibodies against ERK1/2 [Thr202/Tyr204] and EGFR [Tyr1068]
from CST and STAT3 [Tyr705] from Millipore. Endogenous and over-expressed EGFR or
AKT were detected by an EGFR- or AKT-specific rabbit antiserum, respectively (CST). Other
antibodies used were specific for: cleaved caspase-3, phospho-p38 MAPK [Thr180/Tyr182],
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phospho-NFκB p65 [Ser536], cyclin B1, survivin, and NFκB p65 (all purchased from CST).
The anti-phospho-JNK/SAPK [Thr183/Tyr185] antibody was from BD, and the anti-p38α,
IκBα, and JNK 1/3 antibodies were from Santa Cruz Biotechnology (SCB, Dallas, USA). In
some of the assays, loading controls were performed with anti-ERK2 (C-14, SCB), anti-AKT
(CST), anti-β-actin (Millipore), or anti-α-tubulin antibodies (Sigma). After incubation with the
corresponding secondary antibodies conjugated to horseradish peroxidase, protein bands were
revealed by Pierce ECL substrate (Thermo Scientific, MA, USA), according to the manufactur-
er’s protocol. The relative expression of the c-RAF-1-BxB oncogene protein in lung tissues was
quantified after resolving RIPA tissue lysates by SDS-PAGE and using the Advanced Image
Data Analyzer Software (AIDA, Raytest, GmbH, Straubenhardt, Germany). The total band
densities were measured against the local background and normalized to the density of the ap-
propriate beta-actin loading control bands. The values of untreated control samples were taken
as unity.
Animals
All animals were cared for and handled in strict accordance with good animal practices as de-
fined by the EU Council Directive 2010/63/EU, the German Animal Welfare Act “TierSchG”
and to the institutional guidelines of the Westfaelian-Wilhelms University Münster and have
been approved by the responsible authority (Landesamt für Natur, Umwelt und Verbrau-
cherschutz Nordrhein-Westfalen (LANUV-NRW)), Germany.
The anti-tumor activity of DACE was evaluated in a transgenic mouse model of c-RAF-in-
duced lung adenoma (c-RAF-1-BxB mice). The mice contain a lung-targeted expression of the
NH2-terminal deleted human c-RAF-1-BxB oncogenic mutant. The oncogene is controlled by
the human SP-C promoter, allowing selective expression in the type II epithelial cells that line
the lung alveoli. Consequently, in the lungs of c-RAF-1-BxB mice, single tumor foci are detect-
able in the alveolar area by the age of 8 weeks, which develop to solid tumors [28]. Broods of
4 months old homozygous transgenic mice (male) were randomly assigned to the control
group (n = 4) and to the study group (n = 4). DACE was administered daily by intraperitoneal
injections at a dose of 1mg/kg for 21 days. Then, mice were sacrificed under deep anesthesia
with isoflurane, lungs were isolated and analyzed by immunohistochemistry, quantitative real-
time PCR, and Western blotting for the extent of tumor tissue, c-RAF-1-BxB mRNA, and pro-
tein expression, respectively.
Histology and immunohistochemistry
For lung analysis, animals were euthanized and the right lungs fixed with 4% paraformalde-
hyde for histological studies. The left lungs were minced and one half was homogenized in
RNAlater solution for qRT-PCR studies and the other half in RIPA buffer for protein analysis.
Paraffin sections (4μm) of lung specimens were de-paraffinized and stained according to stan-
dard protocols with hematoxylin and eosin. For immunohistochemistry, paraffin sections were
dewaxed, rehydrated, and boiled in 10mM sodium citrate buffer (pH 6.0) for antigen retrieval,
blocked with 5% FBS, and incubated with rabbit-anti-human-RAF antibodies [28] for 1h at
room temperature. The SignalStain Boost IHC Detection Reagent (HRP, Rabbit) from Cell Sig-
naling Technology, Danvers, USA was used to detect the stained protein. Counterstaining with
hematoxylin allowed nuclei visualization. Usually, 4 different sections per mouse sample and 4
mice per experimental setting were quantified. Tumor foci were qualified as RAF-positive foci
containing at least 10 nucleated cells. The area of the RAF-positive tumor foci were then mea-
sured and taken in relation to the total section area of the specimen. Usually, 4 sections per
Cytotoxic and Antitumor Effects of DecucB
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mouse sample representing different lung parts were quantified in a blinded fashion. All analy-
ses were performed in a blinded fashion.
mRNA isolation, cDNA synthesis, and qRT-PCR
Total lung RNA was isolated using Trizol reagent (Invitrogen) according to the manufacturer’s
instructions. cDNA was synthesized from 1μg of total RNA using RevertAid HMinus M-
MuLV Reverse Transcriptase (Fermentas, St. Leon-Rot, Germany) according to the protocol of
the manufacturer. The mRNA levels were determined by TaqMan qRT-PCR using the Light-
Cycler 480II (Roche Diagnostics, Mannheim, Germany). Each cDNA probe was analyzed in
triplicate and specific signals were scored in relation to the signals of two housekeeping gene
transcripts, cytochrome c and GAPDH. The results from different experiments were normal-
ized to the expression of a calibrator probe, which was applied as a positive control in each ex-
periment. Primers for an intronic region of the IL-2 gene were always included to ascertain
that the probes were not contaminated with genomic DNA. The primers used were assigned
using the Universal ProbeLibrary Assay Design Centre at www.roche-applied-science.com/sis
and were: 5’-GCTACCCATGGTCTCATCGT-3’ and 5’-GAAACCCCTCCGAATGCT-3’ for
cytochrome c; 5’-TCACATCCAGTTCTATGCTGGT-3’ and 5’-CAAGGAAACTGGGAA
CATGAA-3’ for IL-2; 5’-GAGGATATGCCTCCCCAGA-3’ and 5’-TTTCTTCACACAGT
CAGCTACCA-3’ for c-RAF-1-BxB; 5’-TGTCCGTCGTGGATCTGAC-3’ and 5’-CCTGCTTC
ACCACCTTCTTG-3’for GAPDH. The changes in gene transcription were ascertained as dif-
ferences between the transcription of the housekeeping genes and the gene of interest using the
2-ΔΔCT method [33].
Statistical analysis
GraphPad Prism 5 Software (San Diego, CA) was used to calculate IC50 values and their 95%
confidence intervals (CI) through a nonlinear fit-curve (log of compound concentration versus
normalized response–variable slope). Statistical analysis was performed by one-way analysis of
variance (ANOVA) followed by the Dunnett test, with P values<0.05 regarded as statistically
significant and P<0.05, P<0.01, P<0.001.
Results
DACE inhibits the growth of A549 cells in vitro and reduces their colony-
forming capability
Initially, we explored whether DACE affects the proliferation of A549 human lung adenocarci-
noma cells using MTT assay. Results of Fig. 2A show that DACE potently inhibited cellular
proliferation in a concentration- and time-dependent manner. The calculated IC50 values for
48h and 72h were 0.42μM and 0.12μM, respectively (equivalent to log value of 2.62 and 2.075).
To test the long term effect of DACE treatment, A549 cells were treated for 48h and then re-
plated with low density into new plates without further treatment. Quantification of colonies
formed twelve days after DACE treatment showed that their number was reduced compared to
control cells to 64% and 76%, respectively, in both tested concentrations (p<0.001 vs. control)
(Fig. 2B).
DACE leads to cell cycle arrest and increased apoptosis in A549 cells
To better understand the mechanism by which cell proliferation was suppressed by DACE, we
investigated the distribution of cell cycle phases of A549 cells following treatment with DACE
by FACS analysis. The untreated control cells showed a typical distribution of G0/G1, G2/M,
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and S phases, but 24h exposure of cells to DACE caused a significant enrichment of cells in the
G2/M phase in a concentration-dependent manner (Fig. 3A). An increase from 10.97±3.04%
to 41.92±0.20% and 46.56±6.01% cells in G2/M phase was detected after the treatment with
0.5μM and 1μM of DACE, respectively (p<0.0001 vs. control). This was followed by a reduc-
tion in G0/G1-phase cells: from 79.75±5.58% in the controls to 46.23±4.03% and 30.88±3.18%
in samples treated with 0.5μM and 1μM of DACE, respectively) (p<0.0001 vs. control). These
results indicated that the compound inhibits the growth of A549 cells by arresting them in the
G2/M cell cycle phase.
Interestingly, the FACS analysis of cell cycle distribution with PI staining showed that the
treatment of A549 cells with DACE results in a significant increase of the sub-G0/G1 peak, sug-
gesting that DACE might induce cell apoptosis. The percentage of G0/G1 cells was increased
from 4.02±0.33% in the control group to 15.90±2.80% after 24h of treatment with 1μM of
DACE (p<0.001 vs. control). To investigate if the observed sub-G0/G1 peak was due to induc-
tion of apoptosis, the cells were double stained with PI (which intercalates in the DNA of ne-
crotic and late apoptotic cells) and Annexin V conjugated–FITC (which only binds early
apoptotic cells). A 12h exposure of cells to 1.0μM of DACE indeed increased the percentage of
apoptotic cells from 6.50±2.41% in the untreated controls to 18.83±4.30% in treated cells
(p<0.05 vs. control; Fig. 3B). Thus, the treatment of A549 cells with DACE not only arrested
cell division but also triggered apoptosis.
Fig 2. Cell and clonogenic growth inhibition by DACE. (A) Human non-small cell lung cancer cells (A549 cells) were treated with different concentrations
of the DACE for 48h and 72h. The growth inhibition effects were determined by MTT assay and the IC50 was calculated by GraphPad Prism 5 software
through a nonlinear fit-curve (log of compound concentration versus normalized response—variable slope). (B) A549 cells were treated with 0.5 and 1 μM of
the DACE for 48h, followed by two washes for compound removal. Then, cells were plated for clonogenic assay; left—representative images of colonies
formed from A549 cells under the different treatment conditions; right—number of colonies after 12 days. ***p<0.001 as compared with control.
doi:10.1371/journal.pone.0117794.g002
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Fig 3. Effects of DACE on cell cycle arrest and apoptosis. (A) A549 cells (5x105) were treated with DACE and analyzed 24h later by flow cytometry. The
values indicate the percentage of A549 cells in the indicated phases of the cell cycle (sub-G0/G1, G0/G1, S and G2/M). *p<0.001 and **p<0.0001 as
compared with control. (B) The A549 cells were treated for 12h with DACE, stained with Annexin V/PI, and submitted to flow cytometry for analysis of the
apoptotic cell proportion. *p<0.05 as compared with control. (C) The A549 cells were either untreated or treated with 0.5μM and 1.0μMDACE for 12h, fixed,
Cytotoxic and Antitumor Effects of DecucB
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DACE induces intense cytoskeleton changes and caspase-3 activation
A prominent feature of DACE was the induction of rapid morphological alterations of A549
cells. Appearance of plasma membrane protrusions, so-called blebs, was observed within min-
utes of DACE treatment, which is a typical feature of apoptosis (data not shown). Since a corre-
lation between surface bleb formation and perturbation of normal actin cytoskeletal
organization has been reported [34], we analyzed whether DACE affects the F-actin microfila-
ment structures. As shown in Fig. 3C, the untreated cells displayed a regularly organized actin
cytoskeleton that was, as is typical for epithelial cells, prominently expressed at cell-cell con-
tacts. However, 12h exposure to 0.5μM or 1.0μM of DACE triggered a collapse of microfila-
ments, resulting in the formation of irregular and globular aggregates of F-actin in the
cytoplasm near to the nuclei (Fig. 3C). This observation further emphasizes the pro-apoptotic
potential of the DACE. It is well known that caspases are executors of the apoptotic process
and are activated by proteolytic cleavage of pro-caspase forms [35]. To evaluate the effects of
DACE on the activation of caspase-3, the cytosolic extracts of treated or untreated control cells
were incubated with a caspase-3-specific substrate. As shown in Fig. 3D, 12h treatment of
A549 cells with 1μM of DACE caused a significant increase in the proteolytic activity of cas-
pase-3. Thus, the morphological signs of apoptosis induction correlate well with caspase-3
activation.
DACE suppresses STAT3 activation and apoptotic-related proteins
In order to understand the mechanism involved in the DACE action on cell cycle and apopto-
sis, we investigated its effect on the levels of cyclin-B1, phospho-STAT3, survivin, and cleaved-
caspase 3 by Western blotting. In accordance with results of cell proliferation analyses, the
expression of cyclin-B1, an important cell cycle regulator [36], was reduced, especially after ex-
posure to 1.0μM of DACE (Fig. 3E). Also, phosphorylation of the latent cytosolic transcription
factor STAT3 that is aberrantly activated in many cancers, including NSCLC and is responsible
for up-regulated expression of several cell cycle regulators and anti-apoptotic proteins, was sig-
nificantly decreased by DACE. In addition, cell treatment with DACE led to reduced expres-
sion of survivin, a well-known anti-apoptotic protein [37], but to increased cleavage of caspase
3. These data are in good agreement with the ability of DACE to activate caspase-3, demon-
strated by the cleavage of a caspase-3-specific substrate (Fig. 3D). Taken together, these results
showed that DACE induced cell cycle arrest and apoptosis by affecting key kinases and other
enzymes that regulate these physiological processes.
DACE is a potent suppressor of the PI3Kinase/AKT signaling pathway
and alters the phosphorylation/activation status of ERK
To detect signaling pathways that might be affected by DACE, human non-small-cell lung can-
cer A549 cells were treated with DACE for 24h followed by stimulation with TNFα (30ng/mL)
for an additional 15 min. TNF activates a broad spectrum of different signaling cascades, thus
allowing narrowing down the affected pathways in the same experimental setting. As PI3K/
AKT and RAS/RAF/ERK pathways are key regulators of cell survival and proliferation, and
their deregulation is commonly found in tumors [4], special attention was paid to these
stained with Hoechst and TRITC-labeled-phalloidin and analyzed by confocal microscopy. Overlay images are shown. (D) The A549 cells were treated for
12h with DACE and their cytosolic fraction was analyzed for changes in the activity of caspase-3. *p<0.05 as compared with control. (E) A549 cells were
treated with DACE for 12h and then subjected to Western blotting using antibodies as indicated. Equal protein loading was confirmed by probing for beta-
actin. Representative images of three independently repeated experiments are shown. The values represent means of three independent experiments and
SD.
doi:10.1371/journal.pone.0117794.g003
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cascades. As shown in Fig. 4A, the TNFα-mediated activation/phosphorylation of both AKT
and ERK was inhibited when A549 cells were treated with either 0.5μM or 1.0μM of the com-
pound. In contrast, the activation state of key signaling proteins after TNF stimulation, such as
p38, JNK, and NF-kappaB p65 as well as the degradation of IκBα, was not significantly
changed upon treatment with DACE (data not shown). To reveal whether DACE affects the
AKT kinase directly, A549 cells were transiently transfected with either empty vector or a wild-
type form of AKT and exposed to 0.5μM and 1.0μM of DACE for 24h. The expression of re-
combinant AKT kinase caused increased AKT phosphorylation in non-stimulated cells and,
interestingly, this basal phosphorylation was not inhibited by DACE. In contrast, phosphoryla-
tion of endogenous AKT was completely inhibited by DACE (Fig. 4B). Overexpression of AKT
also had no effect on inhibition of ERK phosphorylation by DACE. These data indicate that
Fig 4. Effects of DACE on TNFα-mediated activation of signaling pathways. (A) Effect of DACE on the phosphorylation status of AKT and ERK. (B)
Effect of DACE on the phosphorylation status of AKT and ERK in A549 cells transiently transfected with 1μg of wild-type form of AKT or the empty pCMV5
vector. (C) Effect of DACE on the phosphorylation status of PI3K and its regulators PTEN and PDK1. In A, B, and C, the cells were exposed to 0.5μM and
1.0μM of DACE for 24h, stimulated or not for an additional 15 min with 30ng/mL TNFα and analyzed byWestern blotting. (D) Effect of DACE on the
phosphorylation level of EGFR, measured by phosphorylation of its specific Tyr 1068 site and downstream targets AKT and ERK. The A549 cells were
transiently transfected with 1μg human EGFR or its comparable empty-vector control. The cells were exposed to 0.5μM and 1.0μM of DACE for 24h,
stimulated or not with EGF (10ng/mL, 15min) and then analyzed byWestern blotting. (E, F and G) Effect of DACE on the phosphorylation status of ERK in
NIH3T3(k-RAS)- (E), NIH3T3(v-RAF)- transformed cells (F), and NIH3T3(wild-type) cells (G). The cells were simultaneously stimulated with TNFα (30ng/mL)
and exposed or not to 1.0μMDACE for timepoints indicated and analyzed byWestern blotting. Equal protein loading was confirmed by probing for tubulin or
ERK2. The most representative results of three independent experiments are shown.
doi:10.1371/journal.pone.0117794.g004
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upstream components of the AKT signaling cascade, rather than AKT itself, are affected by
DACE. However, while phosphorylation of AKT and PI3K were strongly inhibited by both
0.5μM and 1.0μM of DACE, the phosphorylation of upstream components of PI3K/AKT sig-
naling pathway such as PTEN and PDK1 remained unaffected (Fig. 4C).
DACE inhibits the expression level of EGFR and phosphorylation of
EGFR
Both PI3K and ERK1/2 kinases can be activated by tyrosine kinase receptors [4]. EGFR is ex-
pressed at high levels in a wide range of tumor types and in most lung cancers it has been asso-
ciated with lower rates of survival. Hence, we assessed whether the observed effects of DACE
on PI3K/AKT and ERK1/2 might result from inhibition of EGFR. Human EGFR was overex-
pressed in A549 cells and its phosphorylation was analyzed after stimulation with EGF in the
presence or absence of DACE. Growth factor stimulation resulted in a stronger tyrosine phos-
phorylation signal of the overexpressed receptor than in empty-vector transfected cells, while
incubation with DACE efficiently inhibited phosphorylation in both vector- and EGFR-trans-
fected cells. The effect was concentration-dependent and a concentration of 1μM of DACE was
sufficient to completely prevent the phosphorylation of endogenous EGFR and to efficiently in-
hibit phosphorylation in overexpressing cells (Fig. 4D). Interestingly, overexpression of EGFR
also attenuated the inhibitory effect of DACE on AKT and ERK kinases, suggesting that the
tyrosine kinase receptor is probably the primary target of the compound.
DACE shows selectivity towards malignant transformed cells
In NSCLC, the RAS-RAF-MEK-ERK signaling pathway is frequently hyperactivated [5].
Our experiments showed that DACE efficiently inhibited the activation of this pathway. To
investigate the selectivity and efficiency of DACE towards oncogenic activation of the RAS-RAF-
MEK-ERK pathway, we analyzed established NIH3T3 model cell lines, the oncogenic transfor-
mation of which is based on constitutive oncogenic activation of either RAS or RAF proteins
[28,38,39]. The growth inhibitory effect of DACE towards v-RAF and k-RAS transformed
cells was 31- or 5-times more efficient, respectively, than towards wild-type non-transformed
NIH3T3 cells. For comparison, staurosporine, which is an inhibitor of diverse signaling kinases
had either no effect or even a growth promoting effect compared to wild-type cells (Table 1). In
good agreement with these data, the TNFα-mediated phosphorylation of ERK1/2 was efficiently
blocked by DACE in these cells and the inhibitory effect was more pronounced in v-RAF-com-
pared with k-RAS-transformed NIH3T3 fibroblasts (Fig. 4E-4F).
DACE reduces RAF-induced lung tumors growth in vivo
To study the in vivo relevance of DACE in preventing tumor growth, we injected the com-
pound into the peritoneal cavity of c-RAF-1-BxB mice. These transgenic mice develop multiple
adenomas of type II pneumocyte origin within 4 months after birth. Similar to NIH3T3(v-
RAF) cells, these mice contain a truncated oncogenic version of the human RAF kinase, the ex-
pression of which, however, is restricted to type II lung epithelial cells, as the c-RAF-1-BxB
transgene is driven by the surfactant protein-C (SP-C) promoter [28]. Thus, the development
of NSCLC–like tumors by these mice is driven mainly by the oncogenic human RAF kinase.
Histological analyses of H&E stained lung tissue of 4-month-old mice that have been treated
with 1mg/kg of DACE every second day for 21 days revealed a slight decrease in the number
and size of tumor foci (16% tumor reduction was measured, data not shown). In addition,
immunohistochemical study of lung sections with an antibody recognizing the human c-RAF-
1 kinase confirmed that tumor but not normal lung tissue was affected and that the DMSO
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control did not show any effect (Fig. 5A). At this dose and scheme of treatment, DACE was
well tolerated (data not shown). However, when DACE was administrated at the same dose
(1mg/kg) and for the same time period (21 days), but every single day, which was still tolerated
by the animals, the size of c-RAF-BxB-1-positive tumor foci was significantly reduced com-
pared to the control-treated mice (Fig. 5A-C). As the development of lung adenomas in these
mice mainly depends on expression of the oncogenic human c-RAF-1-BxB [28], it is conceiv-
able that the amount of c-RAF-1-BxB protein or mRNA in lungs will be directly proportional
to the amount of tumor tissue. Indeed, not only the number of tumor colonies and their size
were reduced after treatment of mice with DACE, but also the amount of c-RAF-BxB protein
and mRNA (Fig. 5D-G) and the measured amounts of tumor tissue correlated very well with
the amounts of expressed human c-RAF-1-BxB protein and mRNA (Fig. 5F-5H).
Discussion
Cucurbitacins are a class of highly oxidized tetracyclic triterpenoids that exhibit a wide array of
in vitro and in vivo pharmacological effects, including anti-tumor activity [14–17]. In our pre-
vious studies, we described a novel semisynthetic derivative of cucurbitacin B (DACE) as a po-
tential anti-cancer agent. DACE showed a similar high cytotoxic activity against A549 cells as
its precursor cucurbitacin B [22]. In the plant kingdom there are no natural cucurbitacins that
have an amino group in C-2, and this makes DACE unique in its class. Considering the simple
and short synthetic route starting from cucurbitacin B, this compound could be considered as
a potential drug leader for the generation of new families of bioactive compounds from natural
renewable resources. In this molecule, there are two important features to consider: the double
bond between C1 and C2 with the polar group attached in position 2 (in this case nitrogen),
and the Michael acceptor in the side chain. These functionalities have been validated as phar-
macophores in our previous QSAR work [40]. Changing the hydroxyl group by the amino moi-
ety in C2, DACE has a nucleophilic, basic and hydrogen bond donor/acceptor group instead of
a donor/acceptor group. Furthermore, the C-2 altered its hybridization from sp3 to sp2 show-
ing conformational and structural changes in ring A and the whole molecule. These modifica-
tions could have an effect in the mechanism of action, solubility and bioavailability of this
compound and its derivatives compared with the parental natural compounds.
In this study, we demonstrate for the first time that the semisynthetic derivative of cucurbi-
tacin B (DACE) is a potent suppressor of human NSCLC cell growth in vitro through its effects
Table 1. Growth inhibitory effects and selectivity of DACE and staurosporine towards wild-type and
v-RAF- and k-RAS-transformed NIH3T3 ﬁbroblasts.
Cells DACE Staurosporine
IC50
a (CI 95%) IC50
a (CI 95%)
NIH3T3(wild-type) 17.592 (9.872–31.349) 0.0692 (0.029–0.165)
NIH3T3(v-RAF) 0.561 (0.316–0.998) 0.064 (0.048–0.088)
NIH3T3(k-RAS) 3.559 (1.612–7.857) 12.728 (0.748–21.643)
SIb NIH3T3(v-RAF) 31.4 1.08
SIb NIH3T3(k-RAS) 4 ND
ND = Not determined, since staurosporine was more cytotoxic toward normal NIH3T3 cell line.
aIC50 (μM): inhibitory concentration of 50% cell growth was calculated through a nonlinear ﬁt-curve (log of
compound concentration versus normalized response—variable slope)
bSelectivity index: calculated as IC50 NIH3T3(wild-type)/IC50 NIH3T3(v-RAF) or IC50 NIH3T3(wild-type)/IC50
NIH3T3(k-RAS).
doi:10.1371/journal.pone.0117794.t001
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on the actin-cytoskeleton, EGF receptor and its downstream effectors PI3Kinase, ERK1/2 and
STAT3, and apoptotic proteins. In addition, for the first time, the potential anti-tumor activity
of DACE was shown in a well-established c-RAF-1-induced lung adenoma model in vivo.
Cell cycle analysis suggests that DACE inhibits cell growth via blocking cell division at
the G2/M phase. In addition, treatment of A549 cells resulted in increased apoptosis (Fig. 3B).
These results are in good agreement with recent findings demonstrating that other cucurbita-
cins also induce a G2/M arrest and apoptosis in other human cancer cell lines in vitro [25,41,
42]. To better understand the mechanism of DACE-induced cell cycle arrest and apoptosis, we
firstly investigated the status of key proteins known to regulate G2/M transition and cell death.
The signal transducer and activator of transcription protein 3 (STAT3) is a latent cytosolic
transcription factor that is aberrantly activated in many cancers, including NSCLC. In addition,
STAT3 is responsible for up-regulating the expression of several cell cycle regulators and anti-
apoptotic proteins [43]. Some studies have proposed that cucurbitacins induce inhibitory
effects against several human cancer cell lines via suppression of STAT3 phosphorylation
[44,45]. In the current study, it was clearly demonstrated that the levels of p-STAT3 and cyclin
B1 proteins were decreased in cells treated with DACE (Fig. 3E), suggesting that cell cycle arrest
and apoptosis was at least partially mediated via suppression of cyclin B1 and STAT3 activa-
tion. The transition from one cell cycle phase to another occurs in an orderly fashion and is
regulated by different cellular proteins, such as cyclin B1, which is necessary for the progression
of the cells into and out of M phase of the cell cycle. For several drugs, the anticancer effects are
mediated by cell cycle arrest and involve modulation of the cyclins and cyclin-dependent ki-
nases that regulate cell cycle progression [46]. In the same context, survivin, which is an Inhibi-
tor of Apoptosis Protein (IAP) that plays an important role in both cell cycle regulation and
inhibition of apoptosis, is expressed in cells during the G2/M phase of the cell cycle, followed
by a rapid decay of both mRNA and protein levels at the G1 phase [47]. Inhibition of survivin
expression or disruption of survivin interaction with microtubules leads to apoptosis at the G2/
M phase [48]. Survivin seems to inhibit apoptosis via interactions with multiple regulators of
both intrinsic and extrinsic apoptosis pathways [49]. Some published reports suggest that sur-
vivin could directly suppress the activity of the effector caspase-3 [50], whereas others propose
that survivin primarily acts at the level of an initiator caspase by binding to caspase-9 and/or
neutralizing proapoptotic proteins [51]. Therefore, the decreases in survivin levels have been
found to result in apoptosis [52]. As this protein is also regulated by STAT3 [53], the decrease
in its level by DACE treatment might be because of the inhibition of STAT3. As can be seen in
Fig. 3E, both analyzed concentrations of DACE decreased the expression of survivin, indicating
that survivin might be a regulator of cell division and be required to protect cells
from apoptosis.
Fig 5. Effects of DACE on c-RAF-1-induced lung tumor growth in mice. (A and B) c-RAF-1-BxB transgenic mice were injected daily with either DMSO
(n = 4, A) or 1 mg/kg of DACE (n = 4, B). On day 21, the lungs were fixed, embedded into paraffin and stained for H&E (left images) or for human c-RAF-1
protein (right images). Bars, 1000 μm for upper images and 100 μm for lower images. Arrow heads on upper images indicate lung tumor areas shown
on lower images. (C) The total amount of tumor tissue in the lungs of untreated control mice (n = 4) and DACE-treated mice (n = 4) measured after
immunohistochemistry. The lungs of treated mice exhibited 58% (*p<0.05, t test) less tumor tissue in comparison to untreated control animals. (D) Western
blotting of tumor lysates of untreated control mice (n = 4) and DACE-treated mice (n = 4) for c-RAF-1-BxB expression. Beta-actin was used as a loading
control. (E) Densitometric quantitation of the human c-RAF-1-BxB protein expressed in the lungs of untreated and DACE-treated mice. The lungs of treated
mice exhibited 66% (*p<0.05, t test) less c-RAF-1-BxB expressed protein in comparison to untreated control animals. (G) Total RNA was isolated from the
lungs of untreated mice (n = 4) and DACE-treated mice (n = 4), reverse transcribed, and the expression of c-RAF-1-BxB mRNAwas determined by
quantitative real-time PCR. The expression of c-RAF-1-BxB mRNA was reduced by 37% after systemic treatment with DACE, albeit the means are not
statistically significant when compared by t test. (p>0.05). Relationship between tumor tissue amount and c-RAF-1-BxB protein (F) and c-RAF-1-BxB mRNA
(H) in lungs of all mice analyzed. The relative amounts of tumors, and c-RAF-1-BxB protein and mRNA, were measured by immunohistochemistry, Western
blotting, and qRT-PCR as shown in (A/B, D and G).
doi:10.1371/journal.pone.0117794.g005
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The apoptotic nature of cell death in DACE-treated cells was verified by the ability to acti-
vate the major effector caspase, caspase-3 [35] (Fig. 3D-3E). This confirms the involvement of
this enzyme in the DACE-mediated cell death. Furthermore, DACE induced intense alterations
of the cytoskeleton (Fig. 3C). The actin filamentous organization was rapidly disrupted switch-
ing from a well-developed network that elongated continuously through the cytoplasm in un-
treated cells to an intense accumulation of the F-actin next to the cell nucleus in treated cells.
These findings are in agreement with the present understanding about cucurbitacins, which
suggest a direct modulation of the actin cytoskeleton [23].
Cucurbitacins have shown strong anti-proliferative activity against many human cancer
cells, primarily as inhibitors of the JAK/STAT3 pathway, as previously described in this section.
Blaskovich and co-workers [54] were the first to report that cucurbitacin I rapidly suppresses
phosphorylation of STAT3 in v-Src-transformed NIH3T3 cells and in A549 cells. Consequent-
ly, STAT3 DNA binding and STAT3-mediated gene transcription is inhibited. This cucurbita-
cin also decreased the phosphorylation of JAK without affecting AKT, ERK1/2, or JNK,
suggesting that cucurbitacin I is highly selective for JAK/STAT3. Conversely, cucurbitacin Q
selectively inhibits STAT3 without affecting JAK2, Src, AKT, ERK, or JNK in A549 cells [44].
Nonetheless, five different leukemia cell lines treated with cucurbitacin B showed cell growth
inhibition, which was achieved by suppression of both STAT3 activation and RAF/ERK kinase
pathways [55]. However, when hepatocellular carcinoma (BEL-7402) cells were treated with
cucurbitacin B, c-RAF was inhibited without affecting STAT3 [56]. Another study showed that
cucurbitacin B inhibited the proliferation of seven human osteosarcoma cells lines in vitro,
suppressing ERK, AKT, and mammalian target of rapamycin (mTOR) proteins [57]. Guo and
colleagues[58] showed, for the first time, that cucurbitacin B induced DNA damage in A549
cells mediated by increasing intracellular Reactive Oxygen Species (ROS) formation, which in
turn activated ATM-Chk1-Cdc25C-Cdk1 pathway joined by ATM-p53–14–3–3-σ branch,
leading to the G2/M phase arrest. The same authors [59], demonstrated the DNA damage in-
duced by cucurbitacin B through ROS increase formation, as well as G2/M arrest and apoptosis
in leukemia K562 cells. Another novel target of cucurbitacin B in breast cancer in vitro and in
vivo, which was raised by Gupta and Srivastava [60], is the inhibition of HER2-Integrin signal-
ing. Therefore, cucurbitacins can selectively inhibit different signaling pathways, depending on
the cancer cell type, which led us to study which other pathways are affected by DACE.
Here, we demonstrated that DACE can target directly the epidermal growth factor receptor
(EGFR) (Fig. 4D), suppressing its phosphorylation in a concentration-dependent manner in
both EGFR-overexpressing A549 cells and empty vector control cells, followed by inhibition of
its secondary PI3K/AKT, RAS/ERK, and JAK/STAT3 signaling pathways (Fig. 3E and Fig. 4).
Genetic analysis of NSCLC revealed that the EGFR and its downstream targets, the members
of the mitogenic RAS/RAF/MEK/ERK signalling cascade, are frequently mutated or overex-
pressed in NSCLC types of tumours. The extent of ERK1/2 activation for example correlated
with aggressiveness of NSCLC tumours and was associated with poor prognosis in patients
[61,62] and constitutive EGFR-mediated signaling is usually associated with poor prognosis of
many human malignancies [4,5]. Emerging evidence indicates that the RAF/MEK/ERK path-
way is intimately linked with the PI3K/AKT pathway [63]. In fact, RAS regulates activation of
both kinase pathways resulting in the phosphorylation of many downstream targets. ERK
activation leads to the induction of genes, such as Bcl-2, caspase-9, and cyclin D1, regulating
growth and survival [64]. Likewise, activated AKT exerts its anti-apoptotic activity by prevent-
ing the release of cytochrome c, inhibiting G2/M checkpoint initiation, and directly inactivating
pro-apoptotic factors such as Bad and procaspase-9 [7,65]. Thus, considerable attention has
been given to targeting the EGFR pathway for anti-cancer therapy.
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To explore whether DACE also have an anti-tumor activity in vivo, we decided to target
non-small-cell lung cancer (NSCLC) cells. The neoplastic potential of these tumors is, as al-
ready mentioned, mainly based on oncogenic activation of the EGFR/RAS/RAF/MEK/ERK
signaling axis [66–68]. This pathway was actively blocked by DACE in our in vitro experi-
ments, in both human A549 lung adenocarcinoma and oncogenically transformed mouse
NIH3T3 fibroblasts. In order to analyze the anti-tumor effect specifically and precisely, we
used transgenic mice with lung-targeted expression of oncogenic human c-RAF kinase. The
c-RAF-1-BXB mice develop within 2–4 months after birth multiple type II pneumocyte adeno-
mas, the oncogenic potential of which is, similar to NIH3T3(v-RAF) cells [38,39] and is based
on transformation by v-raf oncogene [28]. As our histological analyses showed, DACE not
only suppressed the progression of RAF-mediated NSCLC in c-RAF-1-BXB transgenic mice
but also reduced the amount of tumor tissue (Fig. 5), which is in good accordance with our in
vitro studies showing a strong anti-proliferative and apoptotic action of DACE on v-raf-trans-
formed NIH3T3(v-RAF) cells.
The in vitro studies have shown that DACE efficiently blocks activation of several signaling
cascades that are related to cell survival and proliferation. However, the exact molecular mech-
anism by which DACE inhibits the function of kinases responsible for activation of these cas-
cades has still to be deciphered. Nonetheless, since the nature of malignant transformation for
both NIH3T3(v-RAF) tissue culture cells and the epithelial lung cells in c-RAF-1-BXB mice is
similar, it is very likely that the mechanism for tumor growth inhibition and cell death in both
cases is similar as well.
In conclusion, we show for the first time that the cucurbitacin B derivative DACE has a
potent anti-NSCLC cell activity by interfering with the EGFR activation and its downstream
signaling. In addition, its anti-tumor activity was verified, also for the first time, in a well-
established c-RAF-induced lung tumor model in vivo. Taken together, these findings suggest
that DACE is a promising lead compound for the development of an anti-lung-cancer drug.
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